Cargando…
Annual reports in medicinal chemistry. Volume 49 /
Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry with an emphasis on emerging topics in the biological sciences that are expected to provide the basis for entirely new future therapies. Reviews on hot topics of interest in small mo...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam :
Academic Press, an imprint of Elsevier,
2014.
|
| Temas: | |
| Acceso en línea: | Texto completo |
| Sumario: | Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry with an emphasis on emerging topics in the biological sciences that are expected to provide the basis for entirely new future therapies. Reviews on hot topics of interest in small molecule drug discovery heavily pursued by industrial research organizations</li><li>Provides preclinical information in the context of chemical structures. Knowledgeable section editors who evaluate invited reviews for scientific rigor. |
|---|---|
| Descripción Física: | 1 online resource (623 pages) |
| Créditos de Producción: | Mer receptor tyrosine kinase : therapeutic opportunities in oncology, virology, and cardiovascular indications / Xiaodong Wang and Stephen Frye -- section 7. Topics in drug design and discovery. Disease-modifying agents for the treatment of cystic fibrosis / Bradley D. Tait and John P. Miller --Advancements in stapled peptide drug discovery & development / Vincent Guerlavais and Tomi K. Sawyer -- Cytochrome P450 enzyme metabolites in lead discovery and development / Sylvie E. Kandel, Larry C. Wienkers and Jed N. Lampe -- 8. Case histories and NCEs. Case history : Forxiga (dapagliflozin), a potent selective SGLT2 inhibitor for treatment of diabetes / William N. Washburn -- Case history : Kalydeco (VS-770, ivacaftor), a CFTR potentiator for the treatment of patients with cystic fibrosis and the G551D-CFTR mutation / Sabine Hadida ... [et al.] -- Case history : Xeljanz (tofacitinib citrate), a first-in-class janus kinase inhibitor for the treatment of rheumatoid arthritis / Mark E. Flanagan ... [et al.] -- New chemical entities entering phase III trials in 2013 / Gregory T. Notte -- To market, to market : 2013 / Joanne Bronson ... [et al.]. |
| Bibliografía: | Includes bibliographical references. |
| ISBN: | 9780128003725 0128003723 |